June 25, 2024 (Toronto, ON) – Supported by OBIO’s Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, Bayer, and its Imaging Core Lab Services team, has partnered with Luxsonic Technologies, Inc. to evaluate and further enhance Luxsonic’s Virtual Imaging Platform (VIP™) as a tool for use in clinical trials. This collaboration between Bayer, Luxsonic and OBIO®, will lead to the development of an enhanced clinical imaging tool for go/no-go decisions, and determination of efficacy, safety, and cost effectiveness of clinical trials.
Bayer’s Imaging Core Lab Services team is a digitally driven, key evidence-generating imaging solution provider for global pharmaceutical and biotechnology companies to facilitate the increasing role of imaging in drug and digital health product development. Luxsonic is dedicated to improving access to radiology services and creating better workflows through the use of augmented reality solutions. Luxsonic’s VIP™ software leverages ethical AI for image analysis and workflow optimization. The LSCTC Centre of Excellence accelerates the health science industry’s use of critical technologies such as ethical AI and fosters the evaluation and adoption of new health technologies across Ontario. This collaboration with Bayer will evaluate and further improve Luxsonic’s virtual reality technology platform to standardize practices, enhance quality, and increase efficiency in the expert radiology clinical trials workflows for diverse assessment criteria.
“Through further enhancement of an intelligent, collaborative, virtual reality-enabled radiology reading platform, Bayer Imaging Core Lab Services, Luxsonic and OBIO’s LSCTC Centre of Excellence aim to reduce product development cycle-time and increase quality and efficiency while reducing costs in clinical trials and Software as Medical Device development,” said Subrata Bose, Head of Bayer’s Imaging Core Lab Services.
“The partnership with Bayer and OBIO’s LSCTC Centre of Excellence represents an important milestone for our company. It’s a great opportunity to expand the use case of our VIP™ software into clinical trials imaging workflow with the goals of standardizing clinical trials practices, improving quality, and efficiency,” said Mike Wesolowski, Founder and CEO of Luxsonic.
“We are thrilled to welcome Bayer as a delivery partner for OBIO’s LSCTC Centre of Excellence to strengthen our shared commitment to advance health tech solutions from early-stage companies in Ontario,” said Dr. Maura Campbell, President and CEO of OBIO®. “This project with Luxsonic is a great example of how ethical AI can be implemented to improve clinical trial workflows and further support wider adoption of the technology in the global market.”
originally published here